Loading
ARROW is the single-arm study behind the second RET inhibitor's thyroid approvals.
ORR 71% in treatment-naive RET-mutant MTC and 60% after prior cabozantinib/vandetanib; 89% in RET-fusion thyroid cancer. Accelerated approval December 2020; the MTC indication was later withdrawn in the US (2023) when the confirmatory trial was not pursued, leaving selpercatinib as the RET-selective option for MTC.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Pralsetinib, RET fusion-positive non-small-cell lung cancer, RET, Non-small-cell lung cancer.
Shares RET fusion-positive non-small-cell lung cancer, RET, Non-small-cell lung cancer.
Shares RET fusion-positive non-small-cell lung cancer, RET, Thyroid cancer, Small-molecule kinase inhibitors.
Shares Pralsetinib, RET fusion-positive non-small-cell lung cancer.
Shares LIBRETTO-431, RET, Thyroid cancer, Small-molecule kinase inhibitors.
Shares LIBRETTO-431, RET fusion-positive non-small-cell lung cancer.
Shares A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRET, LIBRETTO-431, Pralsetinib, RET fusion-positive non-small-cell lung cancer.
Shares A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRET, RET fusion-positive non-small-cell lung cancer.